Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|May 13, 2014

KBI Biopharma Acquires Merck's Biologics Operations

KBI Biopharma acquires Merck's microbial process development and manufacturing operations in Colorado.

KBI Biopharma (KBI), a contract development and manufacturing organization, has signed an agreement with Merck & Co., to acquire Merck’s microbial process development and manufacturing operations in Boulder, Colorado, effective May 1, 2014. Under the agreement, KBI will provide ongoing development and manufacturing services to Merck, as well as to third-party customers.

KBI will also continue to support other ongoing drug development programs for Merck from its two North Carolina facilities.

Source: KBI Biopharma


Related to this article

The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.